Real-world survival outcomes of ribociclib in hormone receptor-positive advanced breast cancer: a national cohort study from Uruguay
This national cohort study from Uruguay demonstrates that ribociclib combined with endocrine therapy provides meaningful survival benefits for patients with advanced HR+/HER2-negative breast cancer in real-world practice, with hepatic metastases and treatment line identified as independent predictors of worse overall and progression-free survival, respectively.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine the human body as a bustling, high-tech city. Inside this city, there are construction crews (cells) that are supposed to build and repair things, but sometimes they get a glitch in their instructions and start building non-stop, ignoring all the "stop" signs. This runaway construction is what we call cancer. In a specific type of breast cancer, the city's construction crews have a special keyhole on their doors called a "hormone receptor." These keys (hormones) usually tell the crews when to work, but in this cancer, the keys keep the doors wide open, letting the crews multiply wildly.
To stop this, doctors use two types of tools. First, they use "Endocrine Therapy," which is like changing the locks or removing the keys so the construction crews can't get in. Second, they use a newer tool called a "CDK4/6 inhibitor" (like Ribociclib), which acts like a speed bump or a traffic jam specifically designed to slow down the crews that are already inside, preventing them from dividing too fast. The big question for doctors and patients is: "Does this combination of tools actually work in the real world, where patients aren't perfect test subjects, or does it only work in the strict, controlled environment of a laboratory?"
This paper tells the story of a massive experiment that happened across the entire country of Uruguay. Instead of a small, controlled lab, the researchers looked at the real-life experiences of 562 women with advanced breast cancer who were treated with Ribociclib and endocrine therapy between 2022 and 2024. The researchers wanted to see how long these women could stay free from their cancer growing again (Progression-Free Survival) and how long they lived overall (Overall Survival) when treated in regular hospitals and clinics.
The study found that the treatment works quite well in the messy, real world. On average, women who started this treatment as their first major therapy saw their cancer stay under control for a median of 12 months. Those who started it as a second treatment (after trying something else first) saw a median of 10 months of control. When looking at the bigger picture of how long patients lived, about 75% of the women were still alive two years after starting treatment.
However, the researchers discovered that not all battles are fought on equal ground. They found that the "line of treatment" mattered: starting with Ribociclib right away gave better results than using it later. But the biggest factor of all was where the cancer had spread. If the cancer had spread to the liver (hepatic metastases), the treatment was less effective at keeping the cancer at bay, and patients with liver involvement had a significantly shorter time before the cancer progressed and a shorter overall survival time. In fact, having cancer in the liver was the only factor that could independently predict a shorter life span, even when accounting for age or whether the patient was treated in a public or private hospital.
Interestingly, the study showed that where a patient lived in Uruguay or whether they used a public or private hospital didn't change the outcome. This suggests that the country's system for funding and distributing this expensive medicine is working fairly well, giving everyone a similar chance at the treatment. While the results were slightly lower than those seen in perfect laboratory trials (which is expected in real life), the study confirms that Ribociclib provides meaningful help to patients in the real world, especially if caught before it spreads to the liver.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.